课题基金 / 基金详情

SGLT-2 Inhibitors and Early Bladder Cancer Events: An International Multi-Centre Study

SGLT-2 Inhibitors and Early Bladder Cancer Events: An International Multi-Centre Study
SGLT-2 抑制剂与早期膀胱癌事件：一项国际多中心研究
批准号：
409881
负责人：
Azoulay Laurent
金额：
$20.9万
依托单位：
Lady Davis Institute for Medical Research (Mtl)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2019
资助国家：
加拿大
项目状态：
已结题
起止时间：
2019-09-01 至 2022-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=409881&lang=en
关键词：
Bladder Cancer Drug Safety Population-Based Type 2 Diabetes

项目摘要

项目成果

Azoulay Laurent的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are a new class of drugs used to treat type 2 diabetes. These drugs have been shown to decrease the risk of fatal and non-fatal cardiovascular outcomes (such as heart attacks, strokes and death) in patie
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cancer pharmacoepidemiology: a population-based assessment of the risks of prescription drugs in vulnerable populations
The use of highly prolactin-elevating antipsychotics and the risk of ovarian and endometrial cancer
The use of beta-blockers and the prevention of cancer-specific mortality
The use of glyburide and the risk of cancer in elderly patients with type 2 diabetes
海外基金